Quick Answer
ANAPTYSBIO, INC reported Stockholders Equity of $37.21 million for the year ending 2025.
- ANAPTYSBIO, INC showed a decrease of -47.5% in Stockholders Equity from 2024 to 2025.
- This data is from ANAPTYSBIO, INC's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $110.12 million | Q2 2017: $109.18 million | Q3 2017: $101.36 million | Q1 2018: $294.53 million | Q2 2018: $284.98 million | Q3 2018: $499.68 million | Q1 2019: $468.16 million | Q2 2019: $448.42 million | Q3 2019: $420.89 million | Q1 2020: $400.56 million | Q2 2020: $381.44 million | Q3 2020: $360.24 million | Q1 2021: $381.94 million | Q2 2021: $385.73 million | Q3 2021: $383.61 million | Q1 2022: $330.75 million | Q2 2022: $304.31 million | Q3 2022: $277.62 million | Q1 2023: $191.09 million | Q2 2023: $148.45 million | Q3 2023: $120.38 million | Q1 2024: $47.78 million | Q2 2024: $9.88 million | Q3 2024: $84.37 million | Q1 2025: $34.02 million | Q2 2025: -$44.73 million | Q3 2025: -$29.42 million.
- Over the full 12 years of available data (2014 to 2025), ANAPTYSBIO, INC's Stockholders Equity has grown by 220.7%.
- Historical annual values: Fiscal year 2025: $37.21 million | Fiscal year 2024: $70.87 million | Fiscal year 2023: $88.10 million | Fiscal year 2022: $262.10 million | Fiscal year 2021: $356.43 million | Fiscal year 2020: $396.73 million | Fiscal year 2019: $405.01 million | Fiscal year 2018: $486.37 million | Fiscal year 2017: $307.58 million | Fiscal year 2016: -$38.25 million | Fiscal year 2015: -$35.18 million | Fiscal year 2014: -$30.84 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: